Newstral
Article
jdsupra.com on 2015-09-04 02:11
PTO Has Broad Discretion in Considering Extraordinary Situations for Patent Term Adjustment - Daiichi Sankyo Co. Ltd. v. Michelle K. Lee
Related news
- Apotex Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- Apotex, Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- Daiichi Sankyo Co. v. Lee (Fed. Cir. 2015)jdsupra.com
- Declaratory Judgment of Non-Infringement of a Disclaimed Patent Warranted in Hatch-Waxman - Apotex Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- LVenous Thromboembolism Product Market SWOT Analysis, Key Indicators, Forecast 2028: Bristol-Myers Squibb Company, Sanofi S.A., Pfizer Inc., Daiichi Sankyo Co. Ltd.liverpoolstudentmedia.com
- Georgia gets $416,000 from Daiichi Sankyo settlementbizjournals.com
- PTAB Discretion to Institute Trials: PTO seeks comments whether to propose rulesjdsupra.com
- Supernus: Federal Circuit Provides Clarity on USPTO Discretion on Patent-Term Adjustment Calculationsjdsupra.com
- Federal Circuit Sides with PTO on Applicant Delay in Patent Term Adjustmentjdsupra.com
- PTO Proposes Standardization of the Patent Term Adjustment Statement Regarding Information Disclosure Statementsjdsupra.com
- U.S. fines drug maker Daiichi Sankyo $39 million over kickbacksThe Japan Times
- FDA Approves New Oral Anticoagulant From Daiichi SankyoForbes
- AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S.wsj.com
- Maryland to share in settlement with drug company Daiichi Sankyothedailyrecord.com
- AstraZeneca agrees potential $6bn oncology collaboration with Daiichi Sankyocambridgeindependent.co.uk
- UM Ventures’ GlycoT Therapeutics grants technology sublicense to Daiichi Sankyothedailyrecord.com
- Apotex Inc. v. Daiichi Sankyo, Inc. (Fed. Cir. 2015)jdsupra.com
- MEsperion to receive $300 million in upfront payments in deal with Daiichi Sankyomarketwatch.com
- AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatmentThe Japan Times